Download the Visual
Protein degrader deals are shifting from platforms to clinically proven targets
More than half of the protein degrader deals announced in the first half of 2026 have gone to clinically proven targets, a break from the years when buyers paid mainly for discovery platforms. Sleuth’s June 2026 analysis of 60 targeted protein degrader deals since January 2019 found that 46 named no single target, but 4 of the 7 deals announced in 2026 through June went to targets that already have an approved or Phase 3 drug: BTK, KRAS, CDK2 and the estrogen receptor (ER).
The shift was clearest on June 8, 2026. Roche committed $700 million upfront, and up to $2.3 billion in total, to Nurix’s BTK degrader bexobrutideg, and the same day Johnson & Johnson agreed to buy Firefly Bio, whose degrader-antibody conjugate platform targets KRAS-driven cancers, for $1 billion in cash.
Platforms dominated degrader dealmaking through 2024
Platform deals with no single target made up every deal in 2019 (4) and 2022 (7), 8 of 9 in 2020 and 9 of 12 in 2024, the peak year. Only 14 of the 60 deals centered on a single disclosed target, 9 of them clinically validated and 5 novel. From 2019 through 2024, only three deals went to validated targets, one each in 2021, 2023 and 2024.
Buyers were paying for the ability to degrade proteins before choosing which proteins mattered, a bet on the modality rather than on specific biology.
In 2026, degrader deals bet on validated biology
Six of the nine validated-target deals came in 2025 and 2026: 2 of 7 deals in 2025 and 4 of 7 in 2026, when platform deals fell to 3. The four 2026 validated-target deals were:
- BTK: Roche’s deal for Nurix’s bexobrutideg, $700 million upfront and $2.3 billion in total potential value
- KRAS: Johnson & Johnson’s acquisition of Firefly Bio, $1.0 billion upfront and in total
- CDK2: Gilead’s option exercise on Kymera’s oral molecular glue KT-200, $45 million upfront and $750 million in total
- ER: Rigel’s license of Arvinas and Pfizer’s vepdegestrant, $85 million upfront and $405 million in total
A validated target is not a validated asset. Firefly’s candidates and KT-200 were preclinical when their deals were announced, so in those deals the target is proven but the drug is not.
Buyers are taking target risk off the table first. In Sleuth’s view, if 2026 is the template, the next degrader deal is more likely to go after an existing target than chase a new one. Sleuth’s Q3 2026 protein degraders report covers the clinical pipeline behind these deals and uses a separate deal set, so its counts differ from this page’s.
Deals announced January 2019 through June 2026, counted by announcement year, covering licensing, option-to-license, platform collaboration and M&A across PROTACs, molecular glues, degrader-antibody conjugates and other degrader types; the set is a defined group of disclosed deals, not every deal ever struck, and this page is a dated snapshot.
Frequently asked questions about protein degrader deals
How many protein degrader deals have been signed since 2019?
Sleuth counted 60 targeted protein degrader deals, including licensing, option-to-license, platform collaboration and M&A, announced from January 2019 through June 2026. Of those, 46 were platform deals with no single target, 9 went to clinically validated targets and 5 to novel targets.
Which 2026 degrader deals went to clinically validated targets?
Four of the seven 2026 deals in Sleuth’s June 2026 analysis: Roche and Nurix at BTK (up to $2.3 billion), Johnson & Johnson and Firefly Bio at KRAS ($1 billion), Gilead and Kymera at CDK2, and Rigel’s license of Arvinas and Pfizer’s vepdegestrant at ER. The other three were platform deals with no single target.
What counts as a clinically validated degrader target?
In Sleuth’s June 2026 analysis, a deal’s single disclosed target counts as clinically validated when at least one approved or Phase 3 drug of any modality is known to hit it, and as novel otherwise. Platform deals with no single target are counted separately.
